CureMatch Partners with SOTERIA

CureMatch, a Serra Capital III portfolio company, announced that they have partnered with SOTERIA Precision Medicine Advisory to support oncologists with personalized cancer treatment options. CureMatch is a digital health company focused on personalized medicine and combination therapy in oncology.

“SOTERIA is proud to work with CureMatch, the leader in predictive analytics for targeted combination cancer treatment,” stated Julia Civardi, Chief Executive Officer of SOTERIA. “This partnership empowers oncologists with specific treatment recommendations from a molecular basis, so patients receive truly personalized precision medicine.”